Janssen announced data from two new analyses of the use of Stelara® (ustekinumab) in Crohn’s disease and ulcerative colitis

Janssen announced data from two new analyses of Stelara® (ustekinumab) for the treatment of adults with Crohn’s disease and ulcerative colitis. Janssen reported that the data from these analyses provides additional support for Stelara® as a first-line option for Crohn’s disease and ulcerative colitis.